Compare
Vivos Inc vs Family Office of America, Inc. vs Pulse Biosciences, Inc. vs Co-Diagnostics, Inc.
| Latest fiscal year | Vivos Inc RDGL | Family Office of America, Inc. FOFA | Pulse Biosciences, Inc. PLSE | Co-Diagnostics, Inc. CODX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $68.4K | $221.8K | $350.0K | $622.5K |
| Revenue growth (YoY) | +144.3% | n/a | n/a | -84.1% |
| Gross margin | -87.4% | 100.0% | -54.0% (computed) | 64.3% |
| Operating margin | n/m | -226.0% | n/m | n/m |
| Net margin | n/m | -222.2% | n/m | n/m |
| Net income | -$3.07M | -$492.7K | -$72.78M | -$46.90M |
| EPS (Diluted) | -$0.01 | -$0.02 | n/a | -$35.25 |
| Operating cash flow | -$2.06M | -$262.2K | -$54.12M | -$29.14M |
| Free cash flow | -$2.16M | n/a | -$54.44M | -$29.84M |
| Cash & equivalents | n/a | n/a | $80.73M | $11.88M |
| Total assets | $1.87M | $1.54M | $94.54M | $24.74M |
| Total liabilities | $206.7K | $878.5K | $13.88M | $4.11M |
| Shareholders' equity | $1.66M | $664.5K | $80.66M | $20.63M |
| Return on year-end equity | -184.6% | -74.2% | -90.2% | -227.3% |
| Shares outstanding | 455.49M | 30.20M | 67.84M | 2.10M |
Revenue, most recent five fiscal years
| Fiscal year | Vivos Inc | Family Office of America, Inc. | Pulse Biosciences, Inc. | Co-Diagnostics, Inc. |
|---|---|---|---|---|
| Latest | $68.4K Ended 2025-12-31 | $221.8K Ended 2025-12-31 | $350.0K Ended 2025-12-31 | $622.5K Ended 2025-12-31 |
| 1 year earlier | $28.0K Ended 2024-12-31 | n/a | $0 Ended 2024-12-31 | $3.92M Ended 2024-12-31 |
| 2 years earlier | $19.5K Ended 2023-12-31 | n/a | $0 Ended 2023-12-31 | $6.81M Ended 2023-12-31 |
| 3 years earlier | $36.5K Ended 2022-12-31 | n/a | $700.0K Ended 2022-12-31 | $34.22M Ended 2022-12-31 |
| 4 years earlier | $14.9K Ended 2021-12-31 | n/a | $1.42M Ended 2021-12-31 | $97.89M Ended 2021-12-31 |